Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 8, 2012, Pages 700-704

  Yildirim, Tolga ^a   Kocak, Timur ^a   Buyukasik, Yahya ^a   Yilmaz, Rahmi ^a   Altun, Bulent ^a   Erdem, Yunus ^a   Arici, Mustafa ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

antifactor Xa; chronic kidney disease; low molecular weight heparin

Indexed keywords

ACETYLSALICYLIC ACID; ANTI BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; CREATININE; ENOXAPARIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTI BLOOD CLOTTING FACTOR 10A BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; BLOOD LEVEL; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; HEART TAMPONADE; HUMAN; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; THROMBOSIS; THROMBOSIS PREVENTION;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BIOLOGICAL MARKERS; BLOOD COAGULATION TESTS; DRUG DOSAGE CALCULATIONS; ENOXAPARIN; FACTOR XA; FEMALE; GLOMERULAR FILTRATION RATE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 84870165654     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328356717f     Document Type: Article

References (23)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1):S1-S266.
2. Spinler SA, Inverso SM, Cohen M, Goodmen SG, Stringer KA, Antman EM. ESSENCE and TIMI 11B Investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146:33-41. (Pubitemid 36851297)
3. Cestac P, Bagheri H, Lapeyre-Mestre M, Sie P, Fouladi A, Maupas E, et al. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Safety 2003; 26:197-207. (Pubitemid 36308105)
4. Nader HB, Walenga JM, Berkowitz SD, Ofosu F, Hoppensteadt DA, Cella G. Preclinical differentiation of low molecular weight heparins. Semin Thromb Hemost 1999; 25 (Suppl 3):63-72. (Pubitemid 29517035)
5. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78:2337-2343.
6. Aguilar D, Goldhaber SZ. Clinical uses of low molecular weight heparins. Chest 1999; 115:1418-1423. (Pubitemid 29230656)
7. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI, American College of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl):141S-159S. (Pubitemid 351892966)
8. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009; 43:1064-1083.
9. Siguret V, Pautas E, Fevrier M, Wipff C, Durand-Gasselin B, Laurent M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti X-a and anti-IIa activities over 10 days. Thromb Haemost 2000; 84:800-804.
10. Brophy DF, Wazny LD, Gehr TW, Comstock TJ, Venitz J. The pharmacokinetics of subcutaneous enoxaparin in end stage renal disease. Pharmacotherapy 2001; 21:169-174. (Pubitemid 32119194)
11. Godable C, Saivin S, Houin G, Sie P, Boneu B, Tonthat H, et al. Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron 1991; 59:543-545.
12. Cadroy Y, Pourrat J, Baladre MF, Saivin S, Houin G, Montastruc JL, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991; 63:385-390.
13. Chow SL, Zammit K, West K, Dannenhoffer M, Lopez-Candeles A. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003; 43:586-590. (Pubitemid 36613117)
14. Sanderink GJ, Guimart CG, OzouxML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002; 105:225-231. (Pubitemid 34260945)
15. Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, et al. TIMI 11A Investigators. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non ST segment elevation acute coronary syndromes. Am Heart J 2002; 143:753-759. (Pubitemid 34595330)
16. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low molecular weight heparin? Arch Intern Med 2002; 162:2605-2609. (Pubitemid 35453500)
17. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Enoxaparin and bleeding complications. A review in patients with and without renal insufficiency. Pharmacotherapy 2000; 20:771-775. (Pubitemid 30457356)
18. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low molecular weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144:673-684. (Pubitemid 46780653)
19. Hirsh J, Raschke R. Heparin and low molecular weight heparin: the seventh ACCP Conference on Antithrombotic and Trombolytic Therapy. Chest 2004; 126 (3 Suppl):188S-203S. (Pubitemid 39297954)
20. Siguret V, Thibault G, Pautas SE, Leizorovicz A. No accumulation of peak anti factor-Xa activity of tinzaparin in elderly patients with moderate-tosevere renal impairment: the IRIS substudy. J Thromb Haemost 2011; 9:1966-1972.
21. Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004; 110:392-398. (Pubitemid 38993847)
22. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low molecular weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122:799-807.
23. Gamba G, Montani N, Anesi E, Palladini G, Lorenzutti F, Perfetti V, et al. Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. Amyloid 1999; 6:273-277. (Pubitemid 30004455)